220 related articles for article (PubMed ID: 11896119)
1. Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol.
Lipshultz SE; Giantris AL; Lipsitz SR; Kimball Dalton V; Asselin BL; Barr RD; Clavell LA; Hurwitz CA; Moghrabi A; Samson Y; Schorin MA; Gelber RD; Sallan SE; Colan SD
J Clin Oncol; 2002 Mar; 20(6):1677-82. PubMed ID: 11896119
[TBL] [Abstract][Full Text] [Related]
2. Continuous Versus Bolus Infusion of Doxorubicin in Children With ALL: Long-term Cardiac Outcomes.
Lipshultz SE; Miller TL; Lipsitz SR; Neuberg DS; Dahlberg SE; Colan SD; Silverman LB; Henkel JM; Franco VI; Cushman LL; Asselin BL; Clavell LA; Athale U; Michon B; Laverdière C; Schorin MA; Larsen E; Usmani N; Sallan SE;
Pediatrics; 2012 Dec; 130(6):1003-11. PubMed ID: 23166343
[TBL] [Abstract][Full Text] [Related]
3. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia.
Lipshultz SE; Lipsitz SR; Sallan SE; Dalton VM; Mone SM; Gelber RD; Colan SD
J Clin Oncol; 2005 Apr; 23(12):2629-36. PubMed ID: 15837978
[TBL] [Abstract][Full Text] [Related]
4. Cardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Children's Oncology Group Randomized Trial Pediatric Oncology Group 9404.
Asselin BL; Devidas M; Chen L; Franco VI; Pullen J; Borowitz MJ; Hutchison RE; Ravindranath Y; Armenian SH; Camitta BM; Lipshultz SE
J Clin Oncol; 2016 Mar; 34(8):854-62. PubMed ID: 26700126
[TBL] [Abstract][Full Text] [Related]
5. Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer.
Lipshultz SE; Lipsitz SR; Mone SM; Goorin AM; Sallan SE; Sanders SP; Orav EJ; Gelber RD; Colan SD
N Engl J Med; 1995 Jun; 332(26):1738-43. PubMed ID: 7760889
[TBL] [Abstract][Full Text] [Related]
6. Doxorubicin cardiotoxicity in children: reduced incidence of cardiac dysfunction associated with continuous-infusion schedules.
Berrak SG; Ewer MS; Jaffe N; Pearson P; Ried H; Zietz HA; Benjamin RS
Oncol Rep; 2001; 8(3):611-4. PubMed ID: 11295089
[TBL] [Abstract][Full Text] [Related]
7. Left ventricular function in patients with toxic cardiomyopathy and with idiopathic dilated cardiomyopathy treated with Doxorubicin.
Katamadze NA; Lartsuliani KP; Kiknadze MP
Georgian Med News; 2009 Jan; (166):43-8. PubMed ID: 19202217
[TBL] [Abstract][Full Text] [Related]
8. Anthracycline dose in childhood acute lymphoblastic leukemia: issues of early survival versus late cardiotoxicity.
Sorensen K; Levitt G; Bull C; Chessells J; Sullivan I
J Clin Oncol; 1997 Jan; 15(1):61-8. PubMed ID: 8996125
[TBL] [Abstract][Full Text] [Related]
9. Protective role of black seed oil in doxorubicin-induced cardiac toxicity in children with acute lymphoblastic leukemia.
Hagag AA; Badraia IM; El-Shehaby WA; Mabrouk MM
J Oncol Pharm Pract; 2020 Sep; 26(6):1397-1406. PubMed ID: 31964219
[TBL] [Abstract][Full Text] [Related]
10. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial.
Lipshultz SE; Scully RE; Lipsitz SR; Sallan SE; Silverman LB; Miller TL; Barry EV; Asselin BL; Athale U; Clavell LA; Larsen E; Moghrabi A; Samson Y; Michon B; Schorin MA; Cohen HJ; Neuberg DS; Orav EJ; Colan SD
Lancet Oncol; 2010 Oct; 11(10):950-61. PubMed ID: 20850381
[TBL] [Abstract][Full Text] [Related]
11. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood.
Lipshultz SE; Colan SD; Gelber RD; Perez-Atayde AR; Sallan SE; Sanders SP
N Engl J Med; 1991 Mar; 324(12):808-15. PubMed ID: 1997853
[TBL] [Abstract][Full Text] [Related]
12. Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia.
Lipshultz SE; Lipsitz SR; Kutok JL; Miller TL; Colan SD; Neuberg DS; Stevenson KE; Fleming MD; Sallan SE; Franco VI; Henkel JM; Asselin BL; Athale UH; Clavell LA; Michon B; Laverdiere C; Larsen E; Kelly KM; Silverman LB
Cancer; 2013 Oct; 119(19):3555-62. PubMed ID: 23861158
[TBL] [Abstract][Full Text] [Related]
13. Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia.
Nysom K; Holm K; Lipsitz SR; Mone SM; Colan SD; Orav EJ; Sallan SE; Olsen JH; Hertz H; Jacobsen JR; Lipshultz SE
J Clin Oncol; 1998 Feb; 16(2):545-50. PubMed ID: 9469339
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of doxorubicin in children with acute lymphoblastic leukemia: multi-institutional collaborative study.
Frost BM; Eksborg S; Björk O; Abrahamsson J; Behrendtz M; Castor A; Forestier E; Lönnerholm G
Med Pediatr Oncol; 2002 May; 38(5):329-37. PubMed ID: 11979457
[TBL] [Abstract][Full Text] [Related]
15. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
Place AE; Stevenson KE; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Supko JG; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJ; Lipshultz SE; Kutok JL; Blonquist TM; Neuberg DS; Sallan SE; Silverman LB
Lancet Oncol; 2015 Dec; 16(16):1677-90. PubMed ID: 26549586
[TBL] [Abstract][Full Text] [Related]
16. Protective Role of Silymarin in Early Doxorubicin-induced Cardiac Dysfunction in Children with Acute Lymphoblastic Leukemia.
Hagag AA; El Shehaby WA; El-Abasy AI; Mabrouk MM
Infect Disord Drug Targets; 2019; 19(2):133-140. PubMed ID: 30073931
[TBL] [Abstract][Full Text] [Related]
17. Does anthracycline administration by infusion in children affect late cardiotoxicity?
Levitt GA; Dorup I; Sorensen K; Sullivan I
Br J Haematol; 2004 Feb; 124(4):463-8. PubMed ID: 14984495
[TBL] [Abstract][Full Text] [Related]
18. Cardiorespiratory status after treatment for acute lymphoblastic leukemia.
Turner-Gomes SO; Lands LC; Halton J; Hanning RM; Heigenhauser GJ; Pai M; Barr R
Med Pediatr Oncol; 1996 Mar; 26(3):160-5. PubMed ID: 8544797
[TBL] [Abstract][Full Text] [Related]
19. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.
Millot F; Suciu S; Philippe N; Benoit Y; Mazingue F; Uyttebroeck A; Lutz P; Mechinaud F; Robert A; Boutard P; Marguerite G; Ferster A; Plouvier E; Rialland X; Behard C; Plantaz D; Dresse MF; Philippet P; Norton L; Thyss A; Dastugue N; Waterkeyn C; Vilmer E; Otten J;
J Clin Oncol; 2001 Apr; 19(7):1935-42. PubMed ID: 11283125
[TBL] [Abstract][Full Text] [Related]
20. Late cardiac effects of anthracycline containing therapy for childhood acute lymphoblastic leukemia.
Rathe M; Carlsen NL; Oxhøj H
Pediatr Blood Cancer; 2007 Jun; 48(7):663-7. PubMed ID: 17405151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
